Innate Pharma (IPHA) News Today $1.76 -0.05 (-2.98%) As of 07/11/2025 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPHA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period IPHA Innate Pharma S.A. - Seeking AlphaJuly 2, 2025 | seekingalpha.comInnate Pharma (NASDAQ:IPHA) Stock Price Down 1% - Should You Sell?June 18, 2025 | marketbeat.comInnate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare ConferencesJune 17, 2025 | businesswire.comInnate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) CongressJune 13, 2025 | businesswire.comInnate Pharma S.A. (NASDAQ:IPHA) Short Interest UpdateMay 30, 2025 | marketbeat.comInnate Pharma (NASDAQ:IPHA) Shares Down 1.1% - Time to Sell?May 28, 2025 | marketbeat.comInnate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare ConferencesMay 27, 2025 | businesswire.comOutcome of Innate Pharma’s 2025 Annual General MeetingMay 23, 2025 | finance.yahoo.comOutcome of Innate Pharma's 2025 Annual General MeetingMay 23, 2025 | businesswire.comInnate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis FungoidesMay 23, 2025 | businesswire.comInnate Pharma Highlights Abstracts Selected for ASCO 2025 Annual MeetingMay 19, 2025 | businesswire.comInnate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 CongressMay 15, 2025 | businesswire.comInnate Pharma S.A. (IPHA) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comInnate Pharma Reports First Quarter 2025 Business Update and Financial ResultsMay 13, 2025 | businesswire.comInnate Pharma (IPHA) Expected to Announce Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comInnate Pharma announces conference call and webcast for Q1 2025 business updateMay 6, 2025 | businesswire.comInnate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-FApril 30, 2025 | businesswire.comInnate Pharma Unveils Promising Preclinical Data for IPH4502 at AACR 2025April 29, 2025 | tipranks.comInnate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual MeetingApril 29, 2025 | businesswire.comHC Wainwright Decreases Earnings Estimates for Innate PharmaApril 29, 2025 | marketbeat.comHC Wainwright Lowers Earnings Estimates for Innate PharmaApril 27, 2025 | marketbeat.comInnate Pharma price target lowered to $11 from $11.50 at H.C. WainwrightApril 25, 2025 | markets.businessinsider.comInnate Pharma Announces €15M Investment by SanofiApril 24, 2025 | businesswire.comInnate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the CompanyApril 23, 2025 | businesswire.comInnate Pharma (NASDAQ:IPHA) Trading Up 1.5% - What's Next?April 20, 2025 | marketbeat.comInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025April 16, 2025 | businesswire.comInnate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its CompositionApril 16, 2025 | businesswire.comInnate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology ForumApril 3, 2025 | finance.yahoo.comEarnings call transcript: Innate Pharma Q4 2024 sees strategic advancesMarch 29, 2025 | uk.investing.comInnate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | insidermonkey.comInnate Pharma (NASDAQ:IPHA) Given "Buy" Rating at HC WainwrightMarch 29, 2025 | marketbeat.comInnate Pharma’s Earnings Call Highlights Progress and ChallengesMarch 28, 2025 | tipranks.comInnate Pharma Reports 2024 Financial Results and UpdatesMarch 27, 2025 | tipranks.comInnate Pharma S.A. (IPHA) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comInnate Pharma Reports Full Year 2024 Financial Results and Business UpdateMarch 27, 2025 | businesswire.comInnate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual MeetingMarch 26, 2025 | businesswire.comInnate Pharma announces its participation in the Life Sciences Van Lanschot Kempen ConferenceMarch 25, 2025 | businesswire.comInnate Pharma: Moving Into The Padcev SpaceMarch 21, 2025 | seekingalpha.comInnate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial ResultsMarch 20, 2025 | businesswire.comInnate Pharma S.A. (NASDAQ:IPHA) Sees Significant Increase in Short InterestMarch 14, 2025 | marketbeat.comInnate Pharma (NASDAQ:IPHA) Trading Up 1.9% - Should You Buy?March 8, 2025 | marketbeat.comInnate Pharma to Participate in the 2025 Leerink Partners Global Healthcare ConferenceFebruary 27, 2025 | businesswire.comInnate: Lacutamab Treatment Program Moves Forward With Potential ExpansionFebruary 20, 2025 | seekingalpha.comInnate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary SyndromeFebruary 17, 2025 | businesswire.comHC Wainwright Reiterates "Buy" Rating for Innate Pharma (NASDAQ:IPHA)February 6, 2025 | marketbeat.comInnate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid TumorsJanuary 27, 2025 | businesswire.comInnate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New YorkJanuary 21, 2025 | businesswire.comCiti Keeps Their Buy Rating on Innate Pharma (IPHA)January 20, 2025 | markets.businessinsider.comInnate Pharma's (IPHA) "Buy" Rating Reiterated at HC WainwrightJanuary 17, 2025 | marketbeat.comInnate Pharma S.A. (NASDAQ:IPHA) Short Interest Down 88.9% in DecemberJanuary 13, 2025 | marketbeat.com Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address IPHA Media Mentions By Week IPHA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPHA News Sentiment▼1.890.99▲Average Medical News Sentiment IPHA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPHA Articles This Week▼11▲IPHA Articles Average Week Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AUTL News STOK News URGN News PHAT News RLAY News ABUS News TNGX News CDXC News DNTH News MGTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IPHA) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IPHA Stock Alerts